Valuation : Atrion Corporation

Market Cap 809M 697M 660M 599M 1.12B 77.33B 1.13B 7.84B 3.02B 39.34B 3.04B 2.97B 124B P/E 2022
28.6x
P/E 2023 34.4x
Enterprise Value 803M 692M 655M 594M 1.11B 76.76B 1.12B 7.78B 2.99B 39.05B 3.02B 2.95B 123B EV / Sales 2022
5.27x
EV / Sales 2023 3.9x
Free-Float
50.88%
Yield 2022
1.47%
Yield 2023 2.3%
3 years 274.98
Extreme 274.98
503.24
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 20/08/2024
Director TitleAgeSince
Director/Board Member 53 20/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/24 Issuer sale

Director

2,991 0.1699%
21/08/24 Issuer sale

Chief Executive Officer

98,614 5.6032%
21/08/24 Issuer sale

Director

499 0.0284%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--%-.--%+1.16% 809M
-1.09%-5.51%-22.83%-0.08% 179B
-1.14%-3.78%-3.86%+11.31% 117B
-0.57%-3.54%+5.43%+79.63% 61.25B
-1.92%-7.24%+9.51%+41.28% 50.24B
-0.23%-4.79%-7.69%-34.16% 48.05B
-1.18%-4.88%+10.01%-22.07% 31.89B
-0.71%-11.89% - - 28.42B
+1.45%+3.08%+32.88%-11.76% 24.23B
+0.49%-8.98%-13.28%+5.27% 21.4B
Average -0.49%-4.66%+1.13%+7.84% 56.23B
Weighted average by Cap. -0.86%-4.24%-6.11%+10.76%

Financials

2022 2023
Net sales 184M 158M 150M 136M 255M 17.53B 256M 1.78B 684M 8.92B 689M 674M 28.18B 169M 146M 138M 125M 235M 16.18B 236M 1.64B 631M 8.23B 636M 622M 26.01B
Net income 35.01M 30.16M 28.56M 25.89M 48.57M 3.34B 48.81M 339M 130M 1.7B 131M 129M 5.38B 19.41M 16.72M 15.84M 14.35M 26.93M 1.85B 27.06M 188M 72.33M 943M 72.9M 71.3M 2.98B
Net Debt -25.21M -21.72M -20.57M -18.64M -34.97M -2.41B -35.15M -244M -93.94M -1.23B -94.68M -92.61M -3.87B -6.02M -5.18M -4.91M -4.45M -8.35M -575M -8.39M -58.29M -22.42M -292M -22.59M -22.1M -924M
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!